[{"address1": "1177 Avenue of the Americas", "address2": "5th floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "332 216 1147", "website": "https://sunshinebiopharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.", "fullTimeEmployees": 46, "companyOfficers": [{"maxAge": 1, "name": "Mr. Camille  Sebaaly", "age": 64, "title": "CFO & Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 720000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steve N. Slilaty Ph.D.", "age": 71, "title": "CEO, President & Chairman", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 430000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marc  Beaudoin", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Abderrazzak  Merzouki", "age": 59, "title": "Chief Science Officer & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 545000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Malek  Chamoun", "age": 38, "title": "Chief Development Officer", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert G. Ferreira", "age": 61, "title": "President of Sunshine Bio Investments Inc", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.1901, "open": 0.0664, "dayLow": 0.0616, "dayHigh": 0.07, "regularMarketPreviousClose": 0.1901, "regularMarketOpen": 0.0664, "regularMarketDayLow": 0.0616, "regularMarketDayHigh": 0.07, "beta": -0.936, "forwardPE": 0.7644444, "volume": 36282199, "regularMarketVolume": 36282199, "averageVolume": 237318, "averageVolume10days": 546630, "averageDailyVolume10Day": 546630, "bidSize": 1000, "askSize": 1300, "marketCap": 1928071, "fiftyTwoWeekLow": 0.0616, "fiftyTwoWeekHigh": 1.4, "priceToSalesTrailing12Months": 0.0947342, "fiftyDayAverage": 0.25356, "twoHundredDayAverage": 0.397, "currency": "USD", "enterpriseValue": -16404947, "profitMargins": -1.31524, "floatShares": 21908717, "sharesOutstanding": 28024300, "sharesShort": 102641, "sharesShortPriorMonth": 114732, "sharesShortPreviousMonthDate": 1703808000, "dateShortInterest": 1706659200, "sharesPercentSharesOut": 0.0037, "heldPercentInsiders": 0.16021, "heldPercentInstitutions": 0.05021, "shortRatio": 1.08, "shortPercentOfFloat": 0.0043, "impliedSharesOutstanding": 28024300, "bookValue": 0.855, "priceToBook": 0.080467835, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -26768336, "trailingEps": -0.59, "forwardEps": 0.09, "enterpriseToRevenue": -0.806, "enterpriseToEbitda": 1.928, "52WeekChange": -0.8051282, "SandP52WeekChange": 0.21078217, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SBFM", "underlyingSymbol": "SBFM", "shortName": "Sunshine Biopharma Inc.", "longName": "Sunshine Biopharma, Inc.", "firstTradeDateEpochUtc": 1644935400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7909c686-ce8d-3dd2-8c10-62221258e4a3", "messageBoardId": "finmb_78729055", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0688, "targetHighPrice": 3.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.0, "targetMedianPrice": 3.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 18846140, "totalCashPerShare": 0.734, "ebitda": -8509198, "totalDebt": 673527, "quickRatio": 4.104, "currentRatio": 4.999, "totalRevenue": 20352428, "debtToEquity": 3.067, "revenuePerShare": 0.849, "returnOnAssets": -0.15754, "returnOnEquity": -0.85867995, "freeCashflow": -7945723, "operatingCashflow": -8332047, "revenueGrowth": 43.859, "grossMargins": 0.35682, "ebitdaMargins": -0.41809, "operatingMargins": -0.13084, "financialCurrency": "USD", "trailingPegRatio": null}]